Stem cell based glioblastoma gene therapy.

Area of Science:

• Oncology
• Regenerative Medicine
• Gene Therapy

Background:

• Glioblastoma multiforme (GBM) remains incurable with current therapies.
• Tumor-initiating glioblastoma cells drive the fatal nature of the disease.
• Mesenchymal stem cells' tumor-tropic ability presents a potential therapeutic delivery system.

Purpose of the Study:

• To review the current knowledge on stem cell-directed glioblastoma therapy.
• To explore the potential of mesenchymal stem cells in targeting glioblastoma stem cells.
• To discuss immunotherapy modalities using mesenchymal stem cells for glioblastoma.

Main Methods:

• Review of preclinical studies on mesenchymal stem cells engineered with suicide genes.
• Analysis of stem cell-based gene therapy, specifically cytosine deaminase expression.
• Discussion of immunotherapeutic approaches using mesenchymal stem cells.

Main Results:

• Engineered mesenchymal stem cells showed significant antitumor responses in preclinical glioblastoma models.
• Mesenchymal stem cells expressing cytosine deaminase demonstrated potential to target glioblastoma stem cells.
• Preclinical data indicate stem cell-based gene therapy may be curative.

Conclusions:

• Stem cell-based gene therapy, particularly prodrug strategies, shows promise for glioblastoma.
• Mesenchymal stem cells offer a viable platform for targeted glioblastoma treatment.
• Encouraging preclinical results warrant the initiation of clinical studies for stem cell-directed glioblastoma therapy.